On October 14, 2021 Fresenius Kabi reported that it has agreed to collaborate with Phlow Corporation, a public benefit company, to expand access to affordable sterile injectables formulated for U.S. children’s hospitals and to help strengthen the supply chain for U.S.-sourced API and essential medicines (Press release, Fresenius, OCT 14, 2021, View Source [SID1234591230]). The companies will work together to supply private-labelled products, co-develop and manufacture novel products and make essential medicines rapidly available in the event of a public health emergency.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!